Delivery Order SPE2DB22D1202-SPE2DB25FVMC6
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a contract value of $17,740.52. This competitively awarded, firm fixed-price delivery order is scheduled for completion by April 25, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a $12,851.51 delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Xifaxan 550 mg tablets (60-count). This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The order is scheduled for completion by September 24, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $6,558.15. This is a firm fixed price delivery order with an ultimate completion date of June 20, 2025, and carries no set-aside designation, indicating it was awarded through competitive procedures. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $17,556.44 firm fixed price delivery order to AmerisourceBergen Drug Corp for 60-tablet bottles of Xifaxan 550 mg on September 12, 2025, with a completion date of September 15, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on April 21, 2025, for the supply of Xifaxan 550 mg tablets (60-count unit dose packaging) with a ceiling value of $18,471.53. This is a firm fixed-price delivery order with an ultimate completion date of April 22, 2025, and no set-aside designation was applied. The award represents a competitively awarded transaction under AmerisourceBergen's broader contract vehicle with DLA Troop...
- The Defense Logistics Agency awarded a $6,885.33 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Xifaxan 550 mg on September 4, 2025, with an ultimate completion date of September 5, 2025. This competitive award, which utilized firm fixed pricing with no set-aside designation, represents a pharmaceutical delivery under the company's existing contract vehicle with DLA. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $3,332.48 to AmerisourceBergen Drug Corp for 60 tablets of Xifaxan 550 mg on September 11, 2025, with completion scheduled for September 12, 2025. This non-competitive, firm fixed-price delivery order represents a small-value transaction under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The work will be performed at the contractor's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for $2,366.60 to supply Xifaxan 550 mg tablets (60-count packages). This is a firm fixed price delivery order with no set-aside designation, executed under open competition. The ultimate completion date is September 24, 2025, with performance to be completed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,867.95 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on September 17, 2025, with an ultimate completion date of September 18, 2025. The contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a...
- The Defense Logistics Agency awarded a $14,427.52 delivery order to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) under a firm fixed-price contract structure. The award was made on August 20, 2025, with an ultimate completion date of August 21, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation. This contract represents a...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVMC6Delivery Order
The Defense Logistics Agency awarded a Delivery Order valued at $5,518.26 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on September 23, 2025, with completion scheduled for September 24, 2025. This firm fixed-price contract represents a non-competitive delivery order placed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is one of numerous pharmaceutical supply transactions AmerisourceBergen executes through its comprehensive DLA IDC, which enables the company to distribute a broad spectrum of medications, vaccines, and medical supplies to support military healthcare systems worldwide. AmerisourceBergen's federal contract portfolio demonstrates consistent capability to fulfill competitive procurement requirements across multiple therapeutic domains, positioning the company as a critical supplier for Department of Defense medical supply chain needs and the broader Defense Health Agency system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.5k | 9/23/25 |